|
May 25, 2005
|
Affinergy Adds Proven Healthcare Executive to Leadership Team
Greg Mossinghoff to join Affinergy to accelerate product programs and partnering transactions.
RESEARCH TRIANGLE PARK, N.C., May 25, 2005 - Affinergy, Inc., a Duke University spinout with a proprietary site-specific biological delivery system, announced today that Gregory J. Mossinghoff will be joining Affinergy July 1, 2005 as a Strategic Advisor. Mossinghoff has previously announced his resignation as President of Inspire Pharmaceuticals effective June 2005.
"Greg is a very talented and experienced executive who will have a major impact on Affinergy's rapid growth," said Peyton Anderson, chief executive officer of Affinergy. "He will be driving a number of strategic projects for Affinergy that leverage his experiences very well. We are all very excited by the energy and experience Greg will bring to our business. Affinergy's ability to recruit Greg validates the operating momentum we are building."
"Affinergy has a tremendously promising technology with a broad range of potential applications to pursue," said Mossinghoff. "I am personally excited by the opportunity to work with and contribute to this very talented business and scientific team. I have had the great fortune and pleasure of getting involved early in a rapidly growing North Carolina company and am enthusiastic about doing it again at Affinergy."
Mr. Mossinghoff has over 17 years of experience in the pharmaceutical industry. He joined Inspire in 1998 and was a member of Inspire's Board of Directors from 2001 to 2004. Mr. Mossinghoff was responsible for business development, strategic planning, commercial operations, fund raising, and other business related activities. He coordinated Inspire's equity financings, which raised over $250 million in private funding, an Initial Public Offering (IPO), and two major secondary public offerings of common stock. He negotiated, coordinated, and closed the company's six major corporate partnership agreements and various academic license agreements totaling more than $150m in stated value. Most notably, he envisioned and championed the company's expansion from its research and early-phase development foundation into its current status as a fully integrated research, development and commercial enterprise and one of the Southeast's leading fully integrated biotech companies.
Prior to joining Inspire, Mr. Mossinghoff was worldwide Director of Business Analysis at Glaxo Wellcome from 1995-1998. Before that, he filled various management positions of increasing responsibility in business development, new product planning, strategic planning, finance and operations at Roche Holding Ltd., Basel, Switzerland and Nutley, NJ. He is a member of the Board of Directors of Medicor Pharmaceuticals, Inc., and various other professional and community organizations including BIO, CED and LES. He advises emerging life science companies in the areas of strategic panning and business development, and is a frequent speaker at local and national healthcare conferences.
About Affinergy, Inc.
Affinergy develops site-specific biological & drug delivery systems using biofriendly binders that selectively adhere to proteins, drugs, cells, and other biomaterial surfaces in order to kickstart biology toward an intended outcome. Affinergy is focused in the orthopedic and biologic drug delivery markets with a growing interest in cardiovascular applications. Affinergy's technology was patented at Duke University and has been incubated at Becton Dickinson's research center in Research Triangle Park. Affinergy was awarded 2005 Innovation of the Year by Frost & Sullivan in the category of Medical Device Coatings.
For more information, visit www.affinergy.com or contact Peyton Anderson at (919) 597-6227.
|
